HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Horner-Glister, E Articles by White, I N H Search for Related Content PubMed PubMed Citation Articles by Horner-Glister, E Articles by White, I N H

¹ MRC Molecular Endocrinology Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester LE2 7 LX, UK
² Cancer Biomarkers and Prevention Group, Biocentre, University of Leicester, University Road, Leicester LE1 7RH, UK
³ MRC Toxicology Unit, Leicester LE1 7RH, UK

(Requests for offprints should be addressed to E Horner-Glister; Cancer Biomarkers and Prevention Group, Biocentre, University of Leicester, University Road, Leicester LE1 7RH, UK; Email: elp8{at}leicester.ac.uk)

Tamoxifen acts as an oestrogen antagonist in the breast reducing cell proliferation, but in the uterus as an oestrogen agonist resulting in increased cell proliferation. Tamoxifen exerts its tissue-specific effects through the oestrogen receptors (ER or ERß). The levels and functions of the two ERs affect the response of the target tissue to oestrogen and tamoxifen. We examined the control of ER stability in breast and uterine cell lines using western blotting and RT-PCR. In MCF-7 breast-derived cells, ER and ERß proteins were rapidly degraded via the proteasome pathway in response to oestradiol; conversely tamoxifen stabilised both receptors. In Ishikawa uterine-derived cells, oestradiol and tamoxifen stabilised ER but led to degradation of ERß by the proteasome pathway. Further investigations showed that oestradiol induced activation of the non-genomic ER/Akt signalling pathway in MCF-7 cells. We have demonstrated that the alternative Erk signalling pathway is activated in Ishikawa cells following oestradiol treatment in the absence of an active proteasome pathway and therefore increased levels of ERß. In conclusion, our data have demonstrated tamoxifen or oestradiol control of ER subtype stability and that non-genomic activation of transcription pathways is cell specific.

This article has been cited by other articles:

				S. Pancholi, A. E Lykkesfeldt, C. Hilmi, S. Banerjee, A. Leary, S. Drury, S. Johnston, M. Dowsett, and L.-A. Martin ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2 Endocr. Relat. Cancer, December 1, 2008; 15(4): 985 - 1002. [Abstract] [Full Text] [PDF]

				S. M Johnson, M. Maleki-Dizaji, J. A Styles, and I. N H White Ishikawa cells exhibit differential gene expression profiles in response to oestradiol or 4-hydroxytamoxifen Endocr. Relat. Cancer, June 1, 2007; 14(2): 337 - 350. [Abstract] [Full Text] [PDF]

				A. J. Chang, D. H. Song, and M. M. Wolfe Attenuation of Peroxisome Proliferator-activated Receptor {gamma} (PPAR{gamma}) Mediates Gastrin-stimulated Colorectal Cancer Cell Proliferation J. Biol. Chem., May 26, 2006; 281(21): 14700 - 14710. [Abstract] [Full Text] [PDF]